A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck

J. H. Schornagel; J. Verweij; P. H M De Mulder; F. Cognetti; J. B. Vermorken; P. Cappelaere; J. P. Armand; J. Wildiers; M. Clavel; A. Kirkpatrick; J. L. Lefebvre

A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck

J. H. Schornagel, J. Verweij, P. H M De Mulder, F. Cognetti, J. B. Vermorken, P. Cappelaere, J. P. Armand, J. Wildiers, M. Clavel, A. Kirkpatrick, J. L. Lefebvre

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

Forty-seven patients with advanced and/or recurrent squamous cell carcinoma of the head and neck were treated with 10-ethyl-10-deaza-aminopterin (10-EdAM), a new analogue of methotrexate. The drug was given as a weekly i.v. bolus injection, starting at 80 mg/m² with two dose increments of 10% if no toxicity was observed after two weeks. Only patients with tumors of the larynx, oral cavity, oropharynx and hypopharynx were included in the trial. Eighty-two percent of the patients had had prior surgery and/or radiotherapy. Forty-four patients were evaluable for response and toxicity. Five CR (12%) and five PR were obtained, yielding a response rate of 24% (CR + PR). The toxicity was similar to that usually seen with methotrexate; stomatitis and skin toxicity were rather pronounced. The data suggest that 10-EdAM has activity similar to that of methotrexate in patients with head and neck cancer.

Original language	English
Pages (from-to)	223-226
Number of pages	4
Journal	Annals of Oncology
Volume	3
Issue number	3
Publication status	Published - 1992

ASJC Scopus subject areas

Cancer Research
Oncology
Statistics, Probability and Uncertainty
Applied Mathematics
Public Health, Environmental and Occupational Health
Neuropsychology and Physiological Psychology
Hematology

Fingerprint Dive into the research topics of 'A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck'. Together they form a unique fingerprint.

Cite this

Schornagel, J. H., Verweij, J., De Mulder, P. H. M., Cognetti, F., Vermorken, J. B., Cappelaere, P., Armand, J. P., Wildiers, J., Clavel, M., Kirkpatrick, A., & Lefebvre, J. L. (1992). A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. Annals of Oncology, 3(3), 223-226.

A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. / Schornagel, J. H.; Verweij, J.; De Mulder, P. H M; Cognetti, F.; Vermorken, J. B.; Cappelaere, P.; Armand, J. P.; Wildiers, J.; Clavel, M.; Kirkpatrick, A.; Lefebvre, J. L.

In: Annals of Oncology, Vol. 3, No. 3, 1992, p. 223-226.

Research output: Contribution to journal › Article › peer-review

Schornagel, J. H. ; Verweij, J. ; De Mulder, P. H M ; Cognetti, F. ; Vermorken, J. B. ; Cappelaere, P. ; Armand, J. P. ; Wildiers, J. ; Clavel, M. ; Kirkpatrick, A. ; Lefebvre, J. L. / A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. In: Annals of Oncology. 1992 ; Vol. 3, No. 3. pp. 223-226.

@article{4442b59e05b94a2795dac8cdafb7a0ea,

title = "A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck",

abstract = "Forty-seven patients with advanced and/or recurrent squamous cell carcinoma of the head and neck were treated with 10-ethyl-10-deaza-aminopterin (10-EdAM), a new analogue of methotrexate. The drug was given as a weekly i.v. bolus injection, starting at 80 mg/m2 with two dose increments of 10% if no toxicity was observed after two weeks. Only patients with tumors of the larynx, oral cavity, oropharynx and hypopharynx were included in the trial. Eighty-two percent of the patients had had prior surgery and/or radiotherapy. Forty-four patients were evaluable for response and toxicity. Five CR (12%) and five PR were obtained, yielding a response rate of 24% (CR + PR). The toxicity was similar to that usually seen with methotrexate; stomatitis and skin toxicity were rather pronounced. The data suggest that 10-EdAM has activity similar to that of methotrexate in patients with head and neck cancer.",

author = "Schornagel, {J. H.} and J. Verweij and {De Mulder}, {P. H M} and F. Cognetti and Vermorken, {J. B.} and P. Cappelaere and Armand, {J. P.} and J. Wildiers and M. Clavel and A. Kirkpatrick and Lefebvre, {J. L.}",

year = "1992",

language = "English",

volume = "3",

pages = "223--226",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "3",

}

TY - JOUR

T1 - A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck

AU - Schornagel, J. H.

AU - Verweij, J.

AU - De Mulder, P. H M

AU - Cognetti, F.

AU - Vermorken, J. B.

AU - Cappelaere, P.

AU - Armand, J. P.

AU - Wildiers, J.

AU - Clavel, M.

AU - Kirkpatrick, A.

AU - Lefebvre, J. L.

PY - 1992

Y1 - 1992

N2 - Forty-seven patients with advanced and/or recurrent squamous cell carcinoma of the head and neck were treated with 10-ethyl-10-deaza-aminopterin (10-EdAM), a new analogue of methotrexate. The drug was given as a weekly i.v. bolus injection, starting at 80 mg/m2 with two dose increments of 10% if no toxicity was observed after two weeks. Only patients with tumors of the larynx, oral cavity, oropharynx and hypopharynx were included in the trial. Eighty-two percent of the patients had had prior surgery and/or radiotherapy. Forty-four patients were evaluable for response and toxicity. Five CR (12%) and five PR were obtained, yielding a response rate of 24% (CR + PR). The toxicity was similar to that usually seen with methotrexate; stomatitis and skin toxicity were rather pronounced. The data suggest that 10-EdAM has activity similar to that of methotrexate in patients with head and neck cancer.

AB - Forty-seven patients with advanced and/or recurrent squamous cell carcinoma of the head and neck were treated with 10-ethyl-10-deaza-aminopterin (10-EdAM), a new analogue of methotrexate. The drug was given as a weekly i.v. bolus injection, starting at 80 mg/m2 with two dose increments of 10% if no toxicity was observed after two weeks. Only patients with tumors of the larynx, oral cavity, oropharynx and hypopharynx were included in the trial. Eighty-two percent of the patients had had prior surgery and/or radiotherapy. Forty-four patients were evaluable for response and toxicity. Five CR (12%) and five PR were obtained, yielding a response rate of 24% (CR + PR). The toxicity was similar to that usually seen with methotrexate; stomatitis and skin toxicity were rather pronounced. The data suggest that 10-EdAM has activity similar to that of methotrexate in patients with head and neck cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026549025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026549025&partnerID=8YFLogxK

M3 - Article

C2 - 1586620

AN - SCOPUS:0026549025

VL - 3

SP - 223

EP - 226

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -